

A LISTING OF THE CLAIMS

1-39. (Canceled).

40. (Previously Presented) A method for stimulating a subject's response to a vaccine comprising administering an immunostimulatory oligonucleotide adjuvant as a vaccine adjuvant with the vaccine to the subject to stimulate the subject's response to the vaccine, wherein the immunostimulatory oligonucleotide comprises a phosphate backbone modification and greater than two unmethylated cytosine-guanine dinucleotides, and wherein the oligonucleotide is at least eight nucleotides in length, wherein the oligonucleotide is linked to a nucleic acid delivery complex.

41. (Previously Presented) The method of claim 40, wherein the nucleic acid delivery complex is a cationic lipid.

42. (Previously Presented) The method of claim 40, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.

43. (Previously Presented) The method of claim 40, wherein the oligonucleotide is ionically linked to or encapsulated in the nucleic acid delivery complex.

44. (Previously Presented) The method of claim 40, wherein the nucleic acid delivery complex is a sterol.

45-53. (Canceled)

54. (Previously Presented) A method for stimulating a subject's response to a vaccine comprising administering an immunostimulatory oligonucleotide adjuvant as a vaccine adjuvant with the vaccine to the subject to stimulate the subject's response to the vaccine, wherein the immunostimulatory oligonucleotide comprises a phosphate backbone modification and an

unmethylated cytosine-guanine dinucleotide, wherein the oligonucleotide is at least eight nucleotides in length and wherein the unmethylated cytosine-guanine dinucleotide is flanked by two 5' purines and two 3' pyrimidines.

55. (Previously Presented) The method of claim 54, wherein the oligonucleotide includes at least two unmethylated cytosine-guanine motifs.

56. (Previously Presented) The method of claim 55, wherein at least one of the at least two unmethylated cytosine-guanine motifs is not palindromic.